At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 40 enrolled
Drug / intervention
temozolomidedrug
Likely dose
temozolomide 75 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial to Evaluate the Effect of Low Dose Temozolomide (TMZ) for 2 Weeks on Brain Tumor O-6-methylguanine-DNA Methyltransferase (MGMT) Activity in Patients With Gliomas.
In Brief
A Phase 2 clinical trial evaluating temozolomide for Glioma. Completed, enrolled 40 participants.
Detailed Summary
The main purpose of this study is to assess the effect of a two-week pre-surgery treatment with low-dose temozolomide (TMZ) on brain tumor methylguanine-DNA (deoxyribonucleic acid) methyltransferase (MGMT) activity in patients with gliomas.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlioma
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2006
First PostedJan 2007
Primary CompletionJan 2010
Study CompletionFeb 2011
TodayJul 2026
First PostedJan 19, 2007
Enrollment StartSep 26, 2006
Primary CompletionJan 11, 2010
Study CompletionFeb 16, 2011
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 19.5 years ago
Interventions
temozolomidedrug
Temozolomide 75 mg/m\^2 daily for 14 days prior to surgery. As standard of care, it could also be given at the same dose for up to 28 days after surgery, per investigator discretion.